A first-in-class kappa opioid receptor (KOR) positioned to fundamentally disrupt the $25 billion post-operative pain market by offering potent analgesia without the abuse potential, respiratory depression, and severe side effects that plague current standard-of-care opioids. The opioid crisis has created a profound and urgent unmet need for effective, non-addictive pain therapeutics. While the KOR has long been a promising target for non-addictive analgesia, previous development attempts have failed due to debilitating side effects like dysphoria and sedation. This program’s innovative mechanism is designed to overcome this historical barrier and has demonstrated a compelling and differentiated profile in robust preclinical models, including non-human primates. The program is currently in the nonclinical phase, with plans of completing all IND-enabling studies by January 2027.